<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02678611</url>
  </required_header>
  <id_info>
    <org_study_id>15BSHE</org_study_id>
    <nct_id>NCT02678611</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Safety and Health Benefits of Basis™ Among Elderly Subjects.</brief_title>
  <acronym>15BSHE</acronym>
  <official_title>A Randomized, Double-blind, Placebo Controlled Study to Evaluate Safety and Health Benefits of Basis™ Among Elderly Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Elysium Health</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>KGK Synergize Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Elysium Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the safety, tolerability and potential health benefits of the
      dietary supplement, Basis. There will be two doses of Basis compared to a placebo. One third
      of subjects will receive the low dose Basis, one third will receive the higher dose Basis and
      one third will receive placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>8 weeks</time_frame>
    <description>Assessment of blood pressure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Blood Parameters</measure>
    <time_frame>8 weeks</time_frame>
    <description>Assessment of safety blood parameters: CBC, electrolytes (Na, K, Cl), kidney function (creatinine), liver function (AST, ALT, GGT and bilirubin)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>8 weeks</time_frame>
    <description>Assessment of heart rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physiological Performance</measure>
    <time_frame>8 weeks</time_frame>
    <description>6 Minute Walk Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physiological Performance</measure>
    <time_frame>8 weeks</time_frame>
    <description>30 Second Chair Stand Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physiological Performance</measure>
    <time_frame>8 weeks</time_frame>
    <description>Physical Activity Scale for the Elderly</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Weight</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Glucose</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid Profile</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life and Sleep Quality</measure>
    <time_frame>8 weeks</time_frame>
    <description>Health Assessment Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life and Sleep Quality</measure>
    <time_frame>8 weeks</time_frame>
    <description>Older People's Quality of Life Questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood NAD+</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Expression Profile of Peripheral Blood Mononuclear Cells</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Pain Assessment</measure>
    <time_frame>8 weeks</time_frame>
    <description>VAS Pain Scale</description>
  </other_outcome>
  <other_outcome>
    <measure>Endothelial Function</measure>
    <time_frame>8 weeks</time_frame>
    <description>EndoPat</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Safety: Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Basis 250</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Basis 500</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Basis 250</intervention_name>
    <arm_group_label>Basis 250</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Basis 500</intervention_name>
    <arm_group_label>Basis 500</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females 60 to 80 (inclusive) years of age

          -  Body Mass Index (BMI) must be 18 to 35 kg/ m2 (±1 kg/m2)

          -  •Be able to make scheduled office visits 4 times during the study

          -  Willing to follow the instructions and complete multiple study questionnaires and
             assessments

          -  Agrees to avoid taking Vitamin B3 (Niacin, Nicotinic acid or niacinamide) supplements
             or multivitamins 14 days prior to randomization and for the duration of the study
             period

          -  Healthy otherwise as determined by laboratory results and medical history

          -  Has given voluntary, written, informed consent to participate in the study

        Exclusion Criteria:

          -  History of any significant chronic disease or any clinically active illness within 3
             months of study entry, including any history of renal or liver impairment, any
             endocrine, inflammatory, cardiovascular, gastro-intestinal, neurological, psychiatric,
             neoplastic or metabolic disease. Clinical significance of disease will be assessed by
             the Qualified Investigator and eligibility determined.

          -  Significant or untreated medical disorders including recent myocardial ischemia or
             infarction, unstable angina, uncontrolled hypertension, AIDS, malignancy, epilepsy,
             and recent cerebrovascular disease

          -  Subjects with or who have recently experienced a traumatic injury, infections or
             undergone surgery

          -  Subjects with history of pellagra or niacin deficiency

          -  Taking lipid lowering drugs

          -  Use of natural health products containing Nicotinamide riboside within 14 days prior
             to randomization and during the course of the study

          -  History of or current diagnosis of any cancer (except for successfully treated basal
             cell carcinoma) diagnosed less than 5 years prior to screening. Volunteers with cancer
             in full remission more than 5 years after diagnosis are acceptable

          -  Has participated in any clinical trial with an investigational medicinal product
             within the past three months prior to the first dose in the current study

          -  Unstable medical conditions

          -  Alcohol use &gt;2 standard alcoholic drinks per day

          -  History of alcoholism or drug abuse within 1 year prior to screening

          -  History of significant allergies

          -  Allergy or sensitivity to any of the investigational product ingredients

          -  Use of medicinal marijuana

          -  Clinically significant abnormal laboratory results at screening

          -  Individuals who are cognitively impaired and/or who are unable to give informed
             consent

          -  Any other condition which in the Investigator's opinion may adversely affect the
             participant's ability to complete the study or its measures or which may pose
             significant risk to the participant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tetyana Pelipyagina, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>KGK Synergize Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>KGK Synergize Inc.</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 3, 2016</study_first_submitted>
  <study_first_submitted_qc>February 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2016</study_first_posted>
  <last_update_submitted>July 28, 2016</last_update_submitted>
  <last_update_submitted_qc>July 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy participants</keyword>
  <keyword>Dietary supplement</keyword>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>Older Adults</keyword>
  <keyword>Basis</keyword>
  <keyword>Nicotinamide riboside</keyword>
  <keyword>Pterostilbene</keyword>
  <pending_results>
    <submitted>March 14, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

